(A) DFS and (B) OS of patients with T-ALL who achieved remission with postinduction treatment according to whether they received HSCT or not in first CR according to MRD status at the EOC. Time originates at landmark (190 days, median time from diagnosis to HSCT). DFS, disease-free survival; EOC, end of consolidation; HSCT, hematopoietic stem cell transplant; MRD, minimal residual disease; OS, overall survival; T-ALL, T-cell acute lymphoblastic leukemia.